The role of carfilzomib in relapsed/refractory multiple myeloma

被引：15

作者：

Yee, Andrew J. ^{[1
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, 55 Fruit St, Boston, MA 02114 USA

来源：

THERAPEUTIC ADVANCES IN HEMATOLOGY | 2021年 / 12卷

关键词：

carfilzomib; multiple myeloma; PROTEASOME INHIBITOR CARFILZOMIB; ONCE-WEEKLY CARFILZOMIB; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; SINGLE-AGENT; IRREVERSIBLE INHIBITOR; SURVIVAL ANALYSIS; SAFETY PROFILE; OPEN-LABEL; BORTEZOMIB;

D O I：

10.1177/20406207211019612

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma.

引用

页数：13

共 50 条

[1] Carfilzomib for relapsed and refractory multiple myeloma
Groen, K.
van de Donk, N. W. C. J.
Stege, C. A. M.
Zweegman, S.
Nijhof, I. S.
CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 2663 - 2675
[2] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
Stewart, A. Keith
FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
[3] A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
Franken, B.
van de Donk, N. W. C. J.
Cloos, J. C.
Zweegman, S.
Lokhorst, H. M.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (06) : 330 - 344
[4] Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Jayaweera, Shansa Pranami E.
Wanigasinghe Kanakanamge, Sacheela Prasadi
Rajalingam, Dharshika
Silva, Gayathri N.
FRONTIERS IN ONCOLOGY, 2021, 11
[5] Carfilzomib In Relapsed, or Relapsed and Refractory, Multiple Myeloma
McCormack, Paul L.
DRUGS, 2012, 72 (15) : 2023 - 2032
[6] A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma
Richard, Shambavi
Jagannath, Sundar
Cho, Hearn Jay
Parekh, Samir
Madduri, Deepu
Richter, Joshua
Chari, Ajai
EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (01) : 31 - 45
[7] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
Watanabe, Takashi
Tobinai, Kensei
Matsumoto, Morio
Suzuki, Kenshi
Sunami, Kazutaka
Ishida, Tadao
Ando, Kiyoshi
Chou, Takaaki
Ozaki, Shuji
Taniwaki, Masafumi
Uike, Naokuni
Shibayama, Hirohiko
Hatake, Kiyohiko
Izutsu, Koji
Ishikawa, Takayuki
Shumiya, Yoshihisa
Kashihara, Tomohisa
Iida, Shinsuke
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 745 - 756
[8] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Shah, Jatin J.
Stadtmauer, Edward A.
Abonour, Rafat
Cohen, Adam D.
Bensinger, William I.
Gasparetto, Cristina
Kaufman, Jonathan L.
Lentzsch, Suzanne
Vogl, Dan T.
Gomes, Christina L.
Pascucci, Natalia
Smith, David D.
Orlowski, Robert Z.
Durie, Brian G. M.
BLOOD, 2015, 126 (20) : 2284 - 2290
[9] An overview of the role of carfilzomib in the treatment of multiple myeloma
Ziogas, Dimitrios C.
Terpos, Evangelos
Kastritis, Efstathios
Dimopoulos, Meletios A.
EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (17) : 1883 - 1897
[10] The emerging role of carfilzomib combination therapy in the management of multiple myeloma
Moreau, Philippe
EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (02) : 265 - 290

← 1 2 3 4 5 →